MDS Nordion of Ottawa has entered into a collaboration to develop new PET radiotracers for cancer diagnostics.
MDS Nordion will work with French contrast developer Guerbet, of Roissy, and Cyceron, a biomedical imaging center in France, to investigate a radiopharmaceutical based on gallium-68 (Ga-68), assessing its functionality, image quality, and commercial feasibility, according to MDS Nordion.
Under the terms of the agreement, MDS Nordion, Guerbet, and Cyceron will provide complementary expertise in radiochemistry, radiolabeling, and targeted delivery of radioisotopes. Guerbet will lead the project for its duration as the scientific coordinator. In addition, each party will provide scientific resources and in-kind contributions to the project, MDS Nordion said.
Related Reading
MDS changes name to Nordion, March 16, 2010
MDS inks deals to sell Pharma Services units, February 12, 2010
MDS names Anderson as chairman, February 2, 2010
MDS to lay off 150 in Toronto, February 1, 2010
MDS blames isotope shortage for poor Q4, January 22, 2010
Copyright © 2010 AuntMinnie.com
